Boston Scientific Corp. (NYSE:BSX) signed a new distribution contract for its cardiac rhythm management products in Japan, as a small band of other companies announced similar deals.
The Natick, Mass.-based medical device giant’s subsidiary Boston Scientific Japan K.K. hired Fukuda Denshi Co. Ltd. to market and sell the devices througout the country.
“Our enhanced sales, distribution and service capabilities will help us better serve Japanese physicians and their patients while broadening our reach and growing our market share in this important market," Boston Scientific Japan president Maulik Nanavaty said in prepared remarks.
- GE Healthcare named exclusive U.S. distributor of Veran ig4 navigation systems
General Electric Co. (NYSE:GE) subsidiary GE Healthcare and Veran, a provider of proprietary 4D registration capability for precise targeting of lesions via its Food & Drug Administration cleared platform, announced a strategic supplier agreement in which GE Healthcare becomes the exclusive distributor and reseller of Veran’s ig4 navigation system in the United States. The deal brings together GE Healthcare’s Innova imaging systems and Veran’s electromagnetic navigation to create a comprehensive interventional oncology solution under a single point of contact.
Read more - Fenwal, GenesisBPS enter agreement for blood-specialty products
Lake Zurich, Ill.-based Fenwal Inc. and Hackensack, N.J.-based GenesisBPS announced they have signed an agreement under which Fenwal will co-market and distribute a range of Genesis-branded products for blood centers, plasma centers and hospitals in the U.S. and Canada. The agreement covers products such as Genesis blood collection mixers and monitors, RapidSeal II tube sealers and automated plasma expressers. Genesis products are designed to help operators improve precision and accuracy in the collection, separation, preparation and storage of blood components.
Read more - Neuro-Biotech Corp. inks exclusive license agreement with Credo-TM Corp. for distribution of its products in Russia
Neuro-Biotech Corp. (OTC:MRES) concluded a business development agreement with Russian Federation-based Credo-TM. The Agreement provides for an exclusive right to distribute all Neuro-Biotech proprietary blood analysis kits and NeuroCeuticals in territories such as Russia, Belarus, Ukraine and Kazakhstan. Furthermore this agreement binds Credo-TM to a minimum yearly order of 500,000 test units for a term of 10 years. Both parties have agreed on an initial price of $55.00 per unit for its initial launch. The pricing for subsequent years may be subject to change. Over the next three months, Credo-TM will be selecting the laboratories mandated to undertake the tests analysis. Neuro-Biotech will be overseeing the technician training program for protocol analysis application.
Read more
